ASCO® 2023 Insights: "Biomarker Analysis of 2 Zolbetuximab Phase 3 Studies (SPOTLIGHT & GLOW) - Global Prevalence of CLDN18.2 in Locally Advanced Unresectable/Metastatic Gastric/GEJ Adenocarcinoma"

507 views
June 12, 2023
Comments 0
Login to view comments. Click here to Login